Introduction/Background This study sought to assess physician reported biomarker screening and treatment decisions in a real-world setting of advanced ovarian cancer (aOC).

Methodology The 2023 Adelphi Real World OC II DSP™ is a cross-sectional survey of physicians treating aOC capturing details of biomarker testing patterns and prescribing habits. Countries included EU5: France, Germany, Italy, Spain, and the United Kingdom (UK), as well as the United States (US), Canada, Japan. Physician-reported data from 343 physicians was collected, with descriptive analyses reported.

Results Detailed results are shown in the table below. Spain (86.7%) and the UK (83.1%) had the highest proportion of aOC patients seen in an academic hospital, and the number of patients seen per typical month was highest in the UK (54.4 compared with 30.0 across all 8 countries). In the EU5, the proportion of patients tested for somatic and germline BRCA1/2 at diagnosis was 55.2% and 50.2%, respectively. Over 90% of EU5 physicians conduct homologous recombination deficiency (HRD) testing; 62% of physicians who conduct BRCA 1/2 testing do so primarily as part of HRD testing. Canadian physicians indicated the lowest proportion of HRD testing (53%). Across all 8 countries, the proportion of patients treated with bevacizumab was 35.5%. Across EU5, this ranged from 22.5% in the UK to 43.1% in France. In Canada, the proportion of patients treated with bevacizumab was 20.3%. The preferred setting for bevacizumab (79%), olaparib (81%), and niraparib (67%) use was 1L among EU5 physicians.

Conclusion Physicians indicated that most patients are tested for HRD and BRCA. The preferred line of therapy for bevacizumab and most PARP inhibitors is 1L.

Disclosures This study was supported by Merck, Sharpe, and Dohme.